Neuronetics Executive and Leadership Team

Daniel Reuvers, the President & Chief Executive Officer at Neuronetics, directs the company's overall strategic vision and operational execution. Reuvers guides the organization's expansion within the mental health sector, focusing on solidifying NeuroStar's position as the leading TMS treatment for depression. This leadership involves driving market penetration and ensuring the company's continued growth through innovation and strategic partnerships. The President & Chief Executive Officer oversees all departments, ensuring alignment with the company's mission to provide superior mental health solutions. Reuvers's focus remains on enhancing the clinical evidence supporting NeuroStar and expanding its accessibility to patients nationwide. The executive's mandate includes fostering a culture of excellence and driving the company's financial performance. Daniel Reuvers ensures the company maintains its competitive edge in the rapidly evolving field of neuromodulation therapies.

Sara Grubbs, the Chief Revenue Officer at Neuronetics, spearheads all revenue-generating activities and commercial strategies. Grubbs directs the sales, marketing, and business development functions, ensuring aggressive growth targets are met and exceeded. This leadership involves optimizing the sales funnel and expanding market reach for NeuroStar Advanced Therapy. The Chief Revenue Officer works closely with the President & Chief Executive Officer to align commercial efforts with the company's strategic objectives. Grubbs's expertise is critical in driving practice success through exceptional ongoing support and maximizing the adoption of TMS technology. By cultivating strong relationships with healthcare providers, Sara Grubbs ensures the widespread availability of effective depression treatment. The executive's responsibilities include developing innovative pricing models and go-to-market strategies that reinforce Neuronetics's industry leadership. Sara Grubbs's efforts directly contribute to the company's financial health and its mission to improve mental well-being.

Corey Anderson, the Chief Technology Officer at Neuronetics, architects and oversees the company's technological infrastructure and innovation pipeline. Anderson drives the development and enhancement of NeuroStar's TMS technology, ensuring its continued leadership in clinical evidence and efficacy for depression treatment. This role involves managing research and development efforts, safeguarding intellectual property, and ensuring the scalability and reliability of the company's technological solutions. The Chief Technology Officer collaborates with other executive leaders to integrate cutting-edge advancements into the product roadmap. Corey Anderson's technical leadership is paramount in maintaining NeuroStar's competitive advantage and expanding its capabilities. The executive's focus includes exploring new applications for TMS and optimizing the user experience for both practices and patients. By championing technological excellence, Corey Anderson supports Neuronetics's mission to deliver advanced mental health therapies.

Geoffrey Grammer, the Vice President, Chief Medical Officer at Neuronetics, provides critical medical and scientific leadership for NeuroStar Advanced Therapy. Grammer oversees the clinical strategy, ensuring the highest standards of patient care and treatment efficacy are maintained. This leadership involves guiding clinical research initiatives, interpreting complex data, and advising on the medical implications of the company's TMS technology for depression. The Vice President, Chief Medical Officer collaborates with the research and development teams to enhance the clinical evidence base supporting NeuroStar. Geoffrey Grammer's insights are essential for validating the technology's effectiveness and expanding its therapeutic applications. The executive's role includes engaging with the medical community and ensuring compliance with all relevant healthcare regulations. Geoffrey Grammer's dedication to advancing mental health treatment underpins Neuronetics's commitment to patient well-being.